Despite the FDA commissioner’s promises of partnership and collaboration, personnel changes and continued federal cuts create ...

In this bonus episode, BioSpace’s Vice President of Marketing ⁠Chantal Dresner⁠ and Careers Editor ⁠Angela Gabriel⁠ take a ...

Thousands of employees across HHS were terminated Monday evening after the U.S. Supreme Court ruled last week that the Trump ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

According to Makary, reducing user fees—which make up just under half of the FDA's budget—could make it easier for smaller ...

The molecule, developed in collaboration with Massachusetts-based Kailera Therapeutics, is headed for a new drug application ...

More than thirty years since its 1993 founding, Catherine Owen Adams and Elizabeth Thompson—the R&D combo that has led Acadia ...

The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its ...

Takeda’s oveporexton improved wakefulness, attention and other key narcolepsy endpoints “with a high degree of statistical significance,” according to Jefferies analysts.

The development saga for the depression molecule has been rocky for years, unable to ease symptoms in multiple late-stage ...

Only with the adoption of digital imaging and AI-powered analysis will next-generation precision oncology therapies reach ...

The FDA cited manufacturing issues but did not flag problems with Ultragenyx’s data package for UX111, with the biotech ...